Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Jun 25, 2025-

Treatment with salanersen shows benefits for SMA children in trial

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, interim results show.

Biogen Announces Advancement of Investigational SMA Drug Salanersen to Registrational Trials Based on Positive Phase 1 Results

"To see a child dosed with gene therapy at age one and still unable to sit at age five then gain that ability within three months of starting salanersen is unexpected and encouraging,” - Dr. Valeria Sansone, principal investigator of the Phase 1 trial   Biogen Inc. announced today that it will advance its investigational spinal muscular atrophy (SMA) treatment, salanersen (BIIB115/ION306), into registrational studies following positive interim d…

Biogen’s Spinraza successor advances to Phase III

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly dosing schedule.The post Biogen’s Spinraza successor advances to Phase III appeared first on Clinical Trials Arena.